GLENMARK
PharmaceuticalsGlenmark Pharmaceuticals ltd
Glenmark Pharmaceuticals Limited or GLENMARK
Glenmark Pharmaceuticals was being incorporated in 1977, and then it entered into the dermatology market by 1979 via the launch of its Candid Cream. Soon it became a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity) with the help of eight molecules in various stages of the clinical development. It also operates in the formulation business in over 95 countries, which also includes India. It has a significant presence in branded generics markets across emerging economies, including India. And its subsidiary, named Glenmark Generics Limited has a fast growing and robust US generics business. It also markets APIs to regulated & semi-regulated countries and employs nearly 6000 people in over 80 countries worldwide. It has approximately twelve manufacturing facilities in over four countries and also has five R&D centers.
The Glenmark was also chosen as one of the "Best Pharma Company in the World – SME" and "Best Company across emerging markets" for 2008 by SCRIP, it is also the most significant selling as well as the most respected pharmaceutical magazine in the world. And then Forbes, which is another leading international publication, recognized Glenmark as the "Best under a Billion Dollar companies in Asia" for 2008.
The vision of this company is to emerge as a leading integrated research-based, global pharmaceutical company and over the decades, it has established itself as a leading player in the discovery of new molecules both NCEs (New Chemical Entity) as well as NBEs (New Biological Entity). Now, they have several molecules in various stages of the preclinical and clinical development, and it is also primarily focused in the areas of Oncology, Respiratory & Dermatology.
The generics business services the requirements of the developed markets like US & Western Europe and API business sells its products in approximately 80 countries worldwide which includes the US, and various other countries in the EU, and South America and India.
And with the 17 manufacturing facilities and 5 R&D centers which are dedicated to the goal of enriching lives across the world and they believe that the real force behind their continued successes is the dedicated employees from across 50 nationalities, committed to creating 'A new way for a new world.'
- Trades at a P/E of 0, with a return on equity (ROE) of 32.3%.
- GLENMARK is trading above 1 of 5 of its key moving averages (10/20/50/100/200-DMA) — a bearish technical setup.
- Year-to-date it is up 9.65%, and up 21.83% over the past year.
- At ₹2,192.00 it sits about 59% of the way up its 52-week range (₹1,792.60–₹2,474.00).
- Offers a dividend yield of 0.18%.
- Market capitalisation stands at ₹61,901 Cr.
Shareholding data syncs daily.
| Year | Revenue | Net Profit | EPS | NPM |
|---|---|---|---|---|
| Mar 2023 | ₹8,221 Cr | ₹1,209 Cr | ₹42.84 | 14.71% |
| Mar 2022 | ₹8,142 Cr | ₹1,998 Cr | ₹70.80 | 24.54% |
| Mar 2021 | ₹10,944 Cr | ₹970 Cr | ₹34.38 | 8.86% |
| Mar 2021 | ₹10,944 Cr | ₹970 Cr | ₹34.38 | 8.86% |
| Mar 2020 | ₹10,641 Cr | ₹776 Cr | ₹27.50 | 7.29% |
| Mar 2020 | ₹10,641 Cr | ₹776 Cr | ₹27.50 | 7.29% |
| Mar 2019 | ₹9,865 Cr | ₹925 Cr | ₹32.78 | 9.38% |
| Mar 2019 | ₹9,865 Cr | ₹925 Cr | ₹32.78 | 9.38% |
| Mar 2018 | ₹9,074 Cr | ₹804 Cr | ₹28.49 | 8.86% |
| Mar 2017 | ₹9,079 Cr | ₹1,109 Cr | ₹39.29 | 12.22% |
| Mar 2016 | ₹7,562 Cr | ₹743 Cr | ₹26.33 | 9.83% |
| Mar 2015 | ₹6,563 Cr | ₹210 Cr | ₹7.31 | 3.2% |
| Company | P/E | Book Value | Sales Growth |
|---|---|---|---|
| SUNPHARMA SUN PHARMACEUTICAL INDUSTRIES LTD. | 39.1 | ₹98.33 | 10.1% |
| MARKSANS MARKSANS PHARMA LTD. | 23.8 | ₹11.85 | 5.8% |
| MOREPENLAB MOREPEN LABORATORIES LTD. | 20.81 | ₹6.43 | 16.6% |
| NEULANDLAB NEULAND LABORATORIES LTD. | 23.48 | ₹542.16 | 9.35% |
| GUFICBIO Gufic BioSciences Ltd. | 24.16 | ₹10.85 | 20.41% |
| DIVISLAB DIVI'S LABORATORIES LTD. | 41.01 | ₹266.77 | 9.47% |
| DRREDDY DR.REDDY'S LABORATORIES LTD. | 19.73 | ₹852.69 | 1.07% |
| RPGLIFE RPG LIFE SCIENCES LTD. | 17.14 | ₹105.02 | 5.73% |
| GLAND Gland Pharma Ltd | 53.6 | ₹242.00 | — |
| ZYDUSLIFE Zydus Lifesciences Ltd | 8.23 | ₹166.00 | 5% |
| SMSPHARMA SMS PHARMACEUTICALS LTD. | 9.58 | ₹42.07 | -8.73% |
| CIPLA CIPLA LTD. | 15.36 | ₹209.71 | 0.7% |
| Date | Client | Type | Qty | Price |
|---|---|---|---|---|
| 25 Oct 2022 | ISHARES CORE EMERGING MARKETS MAURITIUS CO | SALE | 3,02,621 | ₹397.90 |
| 25 Oct 2022 | ISHARES CORE MSCI EMERGING MARKETS ETF | PURCHASE | 3,02,621 | ₹397.90 |
| 25 Oct 2022 | ISHARES INDIA SC MAURITIUS COMPANY | SALE | 39,265 | ₹397.90 |
| 25 Oct 2022 | ISHARES MSCI INDIA SMALL-CAP ETF | PURCHASE | 39,265 | ₹397.90 |
| 17 Oct 2022 | ISHARES CORE EMERGING MARKETS MAURITIUS CO | SALE | 3,02,331 | ₹390.85 |
| 17 Oct 2022 | ISHARES CORE MSCI EMERGING MARKETS ETF | PURCHASE | 3,02,331 | ₹390.85 |
| 17 Oct 2022 | ISHARES INDIA SC MAURITIUS COMPANY | SALE | 39,226 | ₹390.85 |
| 17 Oct 2022 | ISHARES MSCI INDIA SMALL-CAP ETF | PURCHASE | 39,226 | ₹390.85 |
| 11 Oct 2022 | ISHARES CORE EMERGING MARKETS MAURITIUS CO | SALE | 2,94,302 | ₹393.10 |
| 11 Oct 2022 | ISHARES CORE MSCI EMERGING MARKETS ETF | PURCHASE | 2,94,302 | ₹393.10 |
| 11 Oct 2022 | ISHARES INDIA SC MAURITIUS COMPANY | SALE | 38,184 | ₹393.10 |
| 11 Oct 2022 | ISHARES MSCI INDIA SMALL-CAP ETF | PURCHASE | 38,184 | ₹393.10 |
Fundamentals, financials & technicals sourced from niftytrader.in, cached and refreshed periodically.